Kymera Therapeutics, Inc. (KYMR) Q3 2025 10-Q Quarterly Report
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Kymera Therapeutics, Inc. (KYMR) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Kymera Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: Strategic discontinuations of KT-295 and KT-474 programs in mid-2025 reduce pipeline breadth and may delay development timelines
- • Updated risk: Increased operating expenses and net loss of $224.4M for nine months ended Sept 30, 2025 vs $153.1M prior year due to advancing clinical activities
- • Regulatory risk: Clinical holds possible if submitted preclinical/manufacturing data not accepted by FDA, delaying clinical trial initiation
- • Market risk: Dependency on early-stage STAT6 and other preclinical programs for near-term clinical advancement impacts timeline and visibility to revenue
- • Financial risk: $978.7M cash and equivalents as of Sept 30, 2025 expected to fund operations into H2 2028, but capital needs may rise with expanded clinical development
Kymera Therapeutics, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$3M
▼ -26.1% YoY▼ -75.9% QoQ
Net Income
-$82M
▼ -31.5% YoY▼ -7.3% QoQ
Operating Margin
-3346.1%
▼ -141818bp YoY▼ -260930bp QoQ
Net Margin
-2972.0%
▼ -130164bp YoY▼ -230437bp QoQ
ROE
-8.7%
Total Assets
$1.1B
EPS (Diluted)
$-0.94
▼ -13.3% YoY▲ +1.1% QoQ
Operating Cash Flow
-$27M
▲ +46.0% YoY▲ +54.7% QoQ
Source: XBRL data from Kymera Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Kymera Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.